Apr 25, 2019
CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]
Nov 01, 2018
Grifols affirms commitment to patients during Alpha-1 Awareness Month
Sep 25, 2018
Global Hereditary Angioedema Therapeutics Market 2018-2022: Market to Grow at a CAGR of 8.94% with BioCryst Pharmaceuticals, Cipla, CSL, Pharming Group & Shire Dominating
Jun 08, 2018
Global Hereditary Angioedema Market Forecast 2018-2028 - Visiongain Report
May 30, 2018
Asia-Pacific Hereditary Angioedema (HAE) Therapeutics Markets 2016-2018 & 2023
Jan 31, 2018
First John W. Walsh Translational Research Award Granted
Oct 29, 2017
Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
Oct 24, 2017
New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Aug 23, 2017
Hereditary Angioedema Market to be Worth US$3.81 Billion by 2025: Initiatives to Generate Awareness by Physicians and Patient Bodies Drive Growth
Jul 25, 2017
HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Jul 21, 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])
Jun 23, 2017
FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema
Jun 05, 2017
More Than 600 to Hear Top World Experts on Alpha-1, Genetic Cause of Lung and Liver Disease, at National Conference in Chicago